145 related articles for article (PubMed ID: 30549066)
21. A bicentric retrospective study of the correlation of EAU BCR risk groups with
Poterszman N; Merlin C; Margail C; Ouvrard E; Imperiale A; Somme F
Sci Rep; 2024 May; 14(1):10908. PubMed ID: 38740809
[TBL] [Abstract][Full Text] [Related]
22. 18F-PSMA-1007 Uptake in Paget Disease of the Bone: An "Iron Man" Sign.
Alfeeli M; Marafi F; Esmail A; Fathallah WMA; Usmani S
Clin Nucl Med; 2022 Mar; 47(3):249-250. PubMed ID: 34392292
[TBL] [Abstract][Full Text] [Related]
23. Oligodendroglioma in 68Ga-PSMA-11 and 18F-Fluciclovine PET/CT.
Pernthaler B; Nazerani Hooshmand T; Igrec J; Kvaternik H; Aigner RM
Clin Nucl Med; 2021 Apr; 46(4):e231-e232. PubMed ID: 33086280
[TBL] [Abstract][Full Text] [Related]
24. Is 68Ga-Prostate-Specific Membrane Antigen PET/CT Superior than 18F-FDG PET/CT for Evaluation of Metastatic Osteosarcoma?
Can C; Gündoğan C; Kömek H
Clin Nucl Med; 2021 Apr; 46(4):e233-e235. PubMed ID: 33031232
[TBL] [Abstract][Full Text] [Related]
25. PSMA-Ligand Uptake in Disseminated Epidermoid Cysts in a PSMA PET/CT of a Patient With Recurrent Prostate Cancer.
Bohn KP; Alberts I; Mingels C; Rominger A; Afshar-Oromieh A
Clin Nucl Med; 2021 Dec; 46(12):e598-e599. PubMed ID: 34735414
[TBL] [Abstract][Full Text] [Related]
26. Future Imaging of Prostate Cancer: Do We Need More Than PSMA PET/CT?
Vetrone L; Fortunati E; Castellucci P; Fanti S
Semin Nucl Med; 2024 Jan; 54(1):150-162. PubMed ID: 37394289
[TBL] [Abstract][Full Text] [Related]
27. An 18F-MD-PSMA (Multi-dentate PMSA Imaging Agent) PET/CT in Prostate Cancer Relapse: Results of a Retrospective Trial.
Fu H; Liang S; Xu M; Guo J; Liu Q; Kang J; Zhang L; Liu Z; Ding L; Ma Y; Yang B; Yao X; Qi J; Wang H; Cai Y
Curr Radiopharm; 2023 Sep; ():. PubMed ID: 37724670
[TBL] [Abstract][Full Text] [Related]
28. Detection of Diffuse Peritoneal and Omental Metastases From Prostate Cancer With 18F-PSMA-1007 PET/CT.
Ji X; Wang L; Lin J; Tang K
Clin Nucl Med; 2022 Jan; 47(1):e74-e76. PubMed ID: 34238806
[TBL] [Abstract][Full Text] [Related]
29. Docetaxel-Induced Interstitial Pneumonitis Detected on 68Ga-PSMA PET/CT.
Kumar S; Singh H; Das CK; Kumar R; Mittal BR
Clin Nucl Med; 2021 May; 46(5):e268-e269. PubMed ID: 33315676
[TBL] [Abstract][Full Text] [Related]
30. The role of prostate-specific membrane antigen PET/computed tomography in the management of prostate cancer patients: could we ask for more?
Mei R; Farolfi A; Morigi JJ; Fanti S
Curr Opin Urol; 2022 May; 32(3):269-276. PubMed ID: 35552308
[TBL] [Abstract][Full Text] [Related]
31. Incidental Finding of Hibernoma in Prostate-Specific Membrane Antigen PET/CT.
Moreau A; Cruel T; Giraudet AL; Derolland P; Kryza D
Clin Nucl Med; 2021 Sep; 46(9):e469-e470. PubMed ID: 34028409
[TBL] [Abstract][Full Text] [Related]
32. Cost analysis of next-generation imaging in high-risk prostate cancer staging.
Szczesniewski JJ; Tellez Fouz C; García Tello A; de la Rubia Marcos M; García Alonso MP; Llanes González L
Actas Urol Esp (Engl Ed); 2024 May; 48(4):328-334. PubMed ID: 38159802
[TBL] [Abstract][Full Text] [Related]
33. False-Positive 18F-Prostate-Specific Membrane Antigen-1007 PET/CT Caused by Hepatic Multifocal Inflammatory Foci.
Ladrón-de-Guevara D; Canelo A; Piottante A; Regonesi C
Clin Nucl Med; 2021 Feb; 46(2):e80-e83. PubMed ID: 33234935
[TBL] [Abstract][Full Text] [Related]
34. Pretest PSA and Restaging PSMA PET/CT Predict Survival in Biochemically Recurrent Prostate Cancer.
von Eyben R; Hoffmann MA; Soydal C; Virgolini I; Tuncel M; Gauthé M; Kapp DS; von Eyben FE
Biomedicines; 2023 Aug; 11(9):. PubMed ID: 37760775
[TBL] [Abstract][Full Text] [Related]
35. Lessons from a 3-Year Review of PSMA PET-CT in a Tertiary Setting: Can We Fine Tune Referral Criteria by Identifying Factors Predicting Positivity and Negativity?
Pant V; Vinjamuri S; Zanial AZ; Naeem F
Diagnostics (Basel); 2023 Jul; 13(15):. PubMed ID: 37568904
[TBL] [Abstract][Full Text] [Related]
36. Occult Bone Metastases From Hepatocellular Carcinoma Detected on 68Ga-PMSA PET/CT.
Usmani S; Rasheed R; Al Kandari F; Ahmed N
Clin Nucl Med; 2021 Aug; 46(8):661-663. PubMed ID: 33512948
[TBL] [Abstract][Full Text] [Related]
37. Application of 18F-PSMA-1007 PET/MR Imaging in Early Biochemical Recurrence of Prostate Cancer: Results of a Prospective Study of 60 Patients with Very Low PSA Levels ≤ 0.5 ng/mL.
Mojsak M; Szumowski P; Amelian A; Hladunski M; Kubas B; Myśliwiec J; Kochanowicz J; Moniuszko M
Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627213
[TBL] [Abstract][Full Text] [Related]
38. Impact of 68Ga-PSMA PET/CT on Survival and Management in Prostate Cancer.
Algın E; Okudan B; Açıkgöz Y; Sayan H; Bal Ö; Seven B
Curr Med Imaging; 2024 Jan; ():. PubMed ID: 38284703
[TBL] [Abstract][Full Text] [Related]
39. Impact of PSMA PET on Prostate Cancer Management.
Weiner AB; Agrawal R; Valle LF; Sonni I; Kishan AU; Rettig MB; Raman SS; Calais J; Boutros PC; Reiter RE
Curr Treat Options Oncol; 2024 Feb; 25(2):191-205. PubMed ID: 38270802
[TBL] [Abstract][Full Text] [Related]
40. Prostate-Specific Membrane Antigen Expression in Metastatic Angiosarcoma Detected on 18F-PMSA PET/CT: A New Potential Prognostic Marker.
Marafi F; Esmail A; Usmani S
Clin Nucl Med; 2022 Feb; 47(2):e147-e148. PubMed ID: 34172597
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
